Arcturus Therapeutics Provides Mid-Year Updates For ARCT-810, Ornithine Transcarbamylase Deficiency And Cystic Fibrosis Programs
Portfolio Pulse from Benzinga Newsdesk
Arcturus Therapeutics (NASDAQ: ARCT) provided mid-year updates on its ARCT-810 and ARCT-032 programs. The ARCT-810 Phase 2 study in Europe has completed enrollment, with data expected later this year. The U.S. Phase 2 program will expand to include patients with more severe disease. An IND for ARCT-032's Phase 2 study will be submitted within 60 days.
July 01, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics announced significant progress in its ARCT-810 and ARCT-032 programs. The ARCT-810 Phase 2 study in Europe has completed enrollment, with data expected later this year. The U.S. Phase 2 program will expand to include patients with more severe disease. An IND for ARCT-032's Phase 2 study will be submitted within 60 days.
The completion of enrollment for the ARCT-810 Phase 2 study and the upcoming data release are positive milestones. The expansion of the U.S. Phase 2 program and the imminent IND submission for ARCT-032 indicate ongoing progress and potential future catalysts for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100